黄斑変性症治療の市場規模、シェア、成長分析、タイプ別、治療法別、病気の段階別、投与経路別、地域別 - 産業予測、2025～2032年

黄斑変性症治療の世界市場規模は、2023年に167億米ドルと評価され、予測期間（2025-2032年）のCAGRは8.5％で成長し、2024年の181億2,000万米ドルから2032年には348億米ドルに成長する見通しです。

世界の黄斑変性症治療市場は、加齢黄斑変性症（AMD）の有病率の増加と高齢者人口の増加を背景に、急速に発展しています。効果的な治療ソリューションへの需要が高まる中、革新的な抗VEGF療法や徐放性ドラッグデリバリーシステムなど、医学研究の顕著な進歩が患者の予後を改善しています。主な市場動向としては、複数の疾患経路を標的とする併用療法や、遺伝的要因に対処する有望な遺伝子治療アプローチの台頭が挙げられます。しかし、高額な治療費、限られた保険償還範囲、厳しい規制要件などの課題は依然として残っています。注目すべきは、アジア太平洋とラテンアメリカの新興市場に大きな成長機会があることで、人工知能と機械学習技術の統合が診断と治療の強化を約束し、個別化医療への道を開く。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

黄斑変性症治療市場規模：タイプ別

• 市場概要
• 乾燥性加齢黄斑変性
• 滲出性加齢黄斑変性
• その他

黄斑変性症治療市場規模：治療別

• 市場概要
• 抗血管内皮
• その他

黄斑変性症治療市場規模：病気の段階別

• 市場概要
• 初期AMD
• 中等度AMD
• 後期AMD

黄斑変性症治療市場規模：投与経路別

• 市場概要
• 静脈内投与
• 硝子体内経路

黄斑変性症治療市場規模：流通チャネル別

• 市場概要
• 外来手術センター
• 病院
• その他のチャンネル

黄斑変性症治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• Regeneron Pharmaceuticals Inc.（United States）
• AbbVie Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch Health Companies Inc.（Canada）
• Amgen Inc.（United States）
• Biogen Inc.（United States）
• Samsung Bioepis（South Korea）
• PanOptica（United States）
• REGENXBIO Inc.（United States）
• Lineage Cell Therapeutics（United States）
• Ocugen Inc.（United States）
• Olix Pharmaceuticals Inc.（South Korea）
• ONL Therapeutics（United States）
• MeiraGTx（United States）
• OnPoint Vision Inc.（United States）
• Alcon（Switzerland）

結論と推奨事項

Global Macular Degeneration Treatment Market size was valued at USD 16.7 billion in 2023 and is poised to grow from USD 18.12 billion in 2024 to USD 34.8 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global macular degeneration treatment market is rapidly evolving, driven by the increasing prevalence of age-related macular degeneration (AMD) and a rising elderly population. As the demand for effective therapeutic solutions grows, notable advancements in medical research, including innovative anti-VEGF therapies and sustained-release drug delivery systems, have improved patient outcomes. Key market trends highlight the rise of combination therapies, targeting multiple disease pathways, and promising gene therapy approaches that address genetic factors. However, challenges such as high treatment costs, limited reimbursement coverage, and stringent regulatory requirements persist. Notably, emerging markets in Asia-Pacific and Latin America present significant growth opportunities, while the integration of artificial intelligence and machine learning technologies promises to enhance diagnostics and treatment, paving the way for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segmental Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As macular degeneration predominantly impacts individuals over 50, the rise in the global elderly demographic is anticipated to escalate the incidence of this condition. The World Health Organization has projected that the population aged 60 and above will double by 2050. This demographic transformation is poised to enhance the demand for effective treatments targeting macular degeneration, driving market growth. Consequently, healthcare providers and pharmaceutical companies are increasingly focused on developing innovative therapies to address the needs of this expanding population segment, ultimately fostering advancements in treatment options.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces several restraints, one of which is the stringent regulatory requirements that govern the industry. The process for obtaining approval for new treatment options is often protracted and can impose significant costs on pharmaceutical companies. This involves extensive clinical trials, rigorous safety assessments, and detailed regulatory submissions, all of which can hinder the timely introduction of novel therapies. Consequently, the intricate regulatory landscape may discourage some companies from investing in research and development for macular degeneration treatments, ultimately restricting the range and availability of innovative solutions for patients suffering from this condition.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have revolutionized patient care in this sector. The shift towards these digital healthcare solutions facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person consultations. This trend not only enhances patient convenience and compliance but also enables timely interventions and effective disease management, ultimately driving down healthcare costs. Innovations such as home-based visual acuity testing and smartphone imaging devices are becoming integral in monitoring treatment efficacy and disease developments, underscoring a transformative move towards more accessible and efficient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2025-2032)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations